EPIRUS Biopharmaceuticals, Inc.
DelistedCIK 1135906fmd_0ZHHMG63XJHFJ5H8FK77FWVX65Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2016, 25 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|---|
| Total revenues | 17 | 47 | 8 | 13 | 15 | – | – |
| Net interest income | – | – | – | – | (6) | (3) | (1) |
| Cost of revenue | – | – | – | – | – | – | 0 |
| Research and development | 21 | 23 | 35 | 41 | 10 | 16 | 31 |
| Total operating expenses | 38 | 54 | 51 | 55 | 14 | 39 | 53 |
| Operating income | (21) | (7) | (43) | (43) | (14) | (39) | (52) |
| Interest expense | 0 | 0 | 1 | 2 | 1 | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | (0) | 0 | 0 | 0 | (6) | (3) | (0) |
| Income before taxes | 1 | (36) | (43) | (45) | (21) | (42) | (53) |
| Income tax expense | (0) | (1) | (1) | (0) | – | (0) | (1) |
| Net income from continuing operations | 1 | (35) | (42) | (44) | – | (42) | (52) |
| Net income | 15 | (35) | (42) | (44) | (21) | (42) | (52) |